Compare · ACRS vs NVO
ACRS vs NVO
Side-by-side comparison of Aclaris Therapeutics Inc. (ACRS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACRS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $183.15B, about 300.8x ACRS ($608.9M).
- Over the past year, ACRS is up 194.3% and NVO is down 45.7% - ACRS leads by 239.9 points.
- Both names hit the wire about 8 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 18 for ACRS).
- Company
- Aclaris Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $4.37+0.00%
- $41.01-4.51%
- Market cap
- $608.9M
- $183.15B
- 1M return
- -10.27%
- -10.44%
- 1Y return
- +194.28%
- -45.66%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 8
- 8
- Recent ratings
- 18
- 25
Aclaris Therapeutics Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ACRS
- Director Molineaux Christopher P. converted options into 11,580 shares, increasing direct ownership by 20% to 69,536 units (SEC Form 4)
- Director Milano Vincent converted options into 11,580 shares, increasing direct ownership by 67% to 28,896 units (SEC Form 4)
- Director Mehra Anand converted options into 11,580 shares, increasing direct ownership by 2% to 726,403 units (SEC Form 4)
- Director Humphries William D. converted options into 11,580 shares, increasing direct ownership by 35% to 45,105 units (SEC Form 4)
- Director Schiff Andrew N converted options into 11,580 shares, increasing direct ownership by 83% to 25,540 units (SEC Form 4)
- Director Gowen Maxine converted options into 11,580 shares, increasing direct ownership by 53% to 33,334 units (SEC Form 4)
- Aclaris Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
- SEC Form 10-Q filed by Aclaris Therapeutics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care